Navigation Links
Versatile Reporter Vectors for Monitoring Viral Transduction



Determine retroviral transduction efficiency and gene expression in virtually any target cell line

Brenda Rogers Katherine Felts Peter Vaillancourt
Stratagene

We describe three new ViraPort retroviral reporter vectors: pFB-hrGFP Y, pFB-Neo-LacZ ,, and pFB-Luc , which can be used to determine transduction efficiency and gene expression in virtually any target cell line. To assay for expression, use simple fluorescence microscopy or FACS with pFB-hrGFP, carry out a b-galactosidase-activity assay or in situ staining with pFB-Neo-LacZ, or perform a luciferase activity assay with pFB-Luc. These control vectors are available as plasmid DNA as well as transduction-ready, replication-incompetent, VSV-G pseudotyped high-titer retroviral supernatants. The vectors are particularly useful as controls when using the ViraPort retroviral gene expression systems.

We recently introduced a set of human and rodent ViraPort retroviral cDNA expression libraries inserted into the MMLV-based high-titer retroviral vector pFB1,2. These complex cDNA libraries, part of our growing collection of ViraPort retroviral premade libraries, are easily and efficiently introduced into virtually any mitotic cell type for screening based on gene function. The insert capacity of pFB, our MMLV-based replication-defective pFB vector, is approximately 8.0 kb because there is no extraneous sequence between the LTRs. We excluded selectable markers or readily detectable reporter genes from the ViraPort retroviral gene expression systems to ensure that the largest cDNAs possible could be inserted.

Dispensing with marker genes eliminates a direct method for measuring the infectious titer of the resulting retroviral supernatants for a given target cell line, and expression levels cannot be readily determined for the target of choice. To counteract this problem, we constructed and validated a set of high-titer retroviral reporter vectors based on the pFB vector, which can be used to assess transduction efficiency and readily assay for gene expression in infected cells lines. These retroviral reporters are available as plasmid DNA as well as transduction-ready, VSV-G pseudotyped high-titer retroviral supernatants.

pFB-hrGFP Vector

Fig.1

We recently cloned and humanized the green fluorescent protein from the sea pansy Renilla reniformis,* (See page 85). Mammalian tissue culture cells transfected with plasmids harboring the humanized reniformis green fluorescent protein (hrGFP) downstream of the viral promoter were bright green (emission peak: 506 nm), which compares to that typically seen for the humanized, red-shifted A. victoria GFP (EGFP) (data not shown). The coding sequence for hrGFP was inserted between the EcoR I and Xho I sites in the pFB vector to produce the pFB-hrGFP vector (Figure 1A). The vector was then tested in retrovirally transduced cells. To produce virus, a 293-derived cell line was transiently transfected with pFB-hrGFP together with the gag-pol and VSV-G env expression vectors pVPack-GP and pVPack-VSV-G.3 (Figure 1B) Transfections were carried out using the Transfection MBS mammalian transfection kit (Stratagene), modified according to Pear et. al.4 Figure 2 shows that HeLa cells transduced with the virus were highly fluorescent and readily detectable by fluorescence microscopy. To determine transduction efficiencies for the vector, each of five target cell lines were infected with serially diluted viral supernatant and, after a 2-day expression period, the transduction efficiency was determined by FACS. Titers were calculated2,3 for supernatant dilutions that fell within the linear dose:response range for transduction. Titers in excess of 107 cfu/ml were achieved for four out of the five cell lines tested (Table 1). For experiments in which cells were infected at a low multiplicity of infection (MOI) and, thus, harbor only single copies of the hrGFP provirus, fluorescence over background was readily detectable with this vector.

Vector

Dilution

CHO

293

HeLa

COS-7

NIH-3T3

pFB-hrGFP
vector

1:103

1.4 x 107

4.9 x 107

2.0 x 107

2.0 x 107

2.5 x 106

1:104

2.0 x 107

6.3 x 107

2.4 x 107

3.0 x 107

2.8 x 106

pFB-Neo-LacZ
vector

1:102

5.0 x 106

1:103

6.0 x 106

* Titer = (fraction of cells fluorescing over background) x (supernatant dilution/ml) x (2 x 105 cells infected). Titers for pFB-Neo-LacZ vector = (fraction blue cells / total # cells in field) x (supernatant dilution / ml) x (2 x 105 cells infected); titers represent the average for 3 randomly chosen fields for each dilution.

Fig.2

pFB-Neo-LacZ Vector

The use of b-galactosidase as a reporter in retroviral vectors has a number of advantages over other reporters. The enzymatic activity of b-galactosidase can be used as a quantitative measure of gene expression from the viral promoter in a cell line of choice. In addition, virally transduced cells can be visualized in situ by staining with X-gal, and viral titers may be determined both by counting blue cells using light microscopy or by FACS analysis of infected cells following incubation with a fluorescent b-galactosidase substrate. Additionally, by employing the pFB-Neo-LacZ vector, viral titers may also be determined by G418-resistant colony formation due to the presence of the neo marker downstream of the b-galactosidase gene in a bicistronic, IRES-containing cassette (Figure 1A).

We first tested the vector by preparing virus (described above) and infecting CHO cells. Transduced cells were fixed and stained in situ with X-gal using the In Situ b-Galactosidase Staining Kit (Stratagene); the resulting transduced cells stained an intense blue (Figure 2). Viral titers were then determined by counting blue-stained cells as a percentage of the total number of cells visible in a microscopic grid. As indicated in Table 1, titers greater than 106 cfu/ml were achieved for CHO cells (the only cell line tested). In a separate experiment, equivalent titers were determined in parallel by both X-gal staining and selection of neomycin-resistant colony formation.2

pFB-Luc Vector

Fig.3

For certain applications in which a rapid and sensitive assessment of gene expression efficiency from the viral promoter in a target cell of choice is required, luciferase is the reporter of choice. In Figure 3, NIH-3T3 cells infected with VSV-G pseudotyped virions made using pFB-Luc at very low MOIs show a dose-responsive luciferase readout. In addition, they display a significant signal above background at an MOI of 1:20,000, which represents an infection of 200,000 cells with approximately 10 virus particles.

Conclusions

Use ViraPort retroviral reporter vectors in conjunction with ViraPort retroviral premade libraries to reveal the efficiency of any retroviral transduction. When carrying out costly and time-consuming gene delivery experiments, where gene products are not readily detected and where the efficiency of infection and gene expression for cell lines is unknown, valuable information can be determined from using these vectors. These vectors are useful in the ViraPort retroviral premade libraries. Stratagene offers three different vectors for the greatest versatility. The standard control vector pFB-Luc is supplied with each ViraPort retroviral premade library, and the pFB Neo-LacZ and pFB-hrGFP vectors are available separately.


'"/>

Source:


Page: All 1 2 3 4 5 6

Related biology technology :

1. A Versatile Power Supply for All Electrophoresis Applications
2. Versatile Vectors for Ponasterone A- Inducible Control of Gene Expression in Mammalian Cells
3. Versatile Transfection Reagent Offers Low Toxicity and Consistent Performance
4. pSilencer 4.1-CMV: Versatile Vectors for Expression of siRNA, miRNA, and mRNA
5. New Mammalian Expression Vectors Employ Stable, High-Level Fluorescence Humanized Renilla GFP Reporter
6. Stable HeLa Luciferase Reporter Cell Lines Expressing GAL4 Fusion Transactivators
7. New Reporter Plasmids for Studying Interferon-Stimulated Signal Transduction Pathways
8. Genetic Reporter Systems
9. Genetic Reporter Systems
10. Detection of Reporter Gene Activity in Cell Cultures and Murine Epidermis After Helios Gene Gun-Mediated Particle Bombardment
11. A Microtiter-based Assay for the Determination of ID50s of b-lactamase Inhibitors Employing Reporter Substrates Detected at UV or Visible Wavelengths (MaxLine Application Note #20)
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Versatile Reporter Vectors for Monitoring Viral Transduction

(Date:11/24/2014)... November 24, 2014 Continental Clinical ... populations into clinical trials at its mid-Atlantic late-phase ... “Continental was created with the idea of closing ... fundamental role in medical advances," said Continental's CEO, ... experiment to the immortal cell line of Henrietta ...
(Date:11/24/2014)... , Nov. 24, 2014  Spherix Incorporated (Nasdaq: ... committed to the fostering and monetization of intellectual ... VTech Telecommunications Ltd.,  Case No. 3:13-cv-03494-M and  Spherix ... 3:13-cv-03496-M, both in the United States District Court ... . On November 21, ...
(Date:11/22/2014)... November 21, 2014 Two new educational webinars ... comes next for ALS research and how the pharmaceutical industry ... the Ice Bucket Challenge: Where Does the ALS Money Go? ... 2 December 2014, Time: 1:30pm ET, Register to ... speaker Dr. Merit Cudkowicz, Julianne Dorn Professor of Neurology at ...
(Date:11/22/2014)... 2014 CannLabs, Inc. (OTCQB: ... and scientific testing methodologies relating to cannabis, today announced ... line of credit from an existing stockholder of the ... secured this commitment from one of our existing stockholders,” ... “This capital will help accelerate our planned expansions into ...
Breaking Biology Technology:At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 2At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 3Markman Hearing Held as Scheduled in VTech and Uniden Cases 2DrugDev Webinars in December to Explore What Comes Next for ALS Research and How We Can Make Life Easier for Clinical Sites 2CannLabs Secures $750,000 Line Of Credit 2
... (NASDAQ: NBIX ) announced today that it ... initial cohort of Tardive Dyskinesia patients using its proprietary ... this data, the Company is initiating the Investigational New ... Drug Administration (FDA). "We are very pleased ...
... announces that a new market research report is ... Sequencing - technologies, markets and companies ... report briefly reviews basics of human genome variations, ... large and small sequencers are described as well ...
... 2011 Caliper Life Sciences, Inc. (NASDAQ: ... for drug discovery and life-sciences research, today announced that ... formed a research collaboration with Denver-based Catholic Health Initiatives ... The health care system,s Center for Translational Research ...
Cached Biology Technology:Neurocrine Biosciences Announces Successful Phase IIa Clinical Trial for VMAT2 Inhibitor 2Neurocrine Biosciences Announces Successful Phase IIa Clinical Trial for VMAT2 Inhibitor 3Neurocrine Biosciences Announces Successful Phase IIa Clinical Trial for VMAT2 Inhibitor 4Reportlinker Adds DNA Sequencing - Technologies, Markets and Companies 2Caliper Announces New Oncology Research Collaboration 2Caliper Announces New Oncology Research Collaboration 3
(Date:11/18/2014)...   News Highlights: ... The Partners Data Lake, an agile data and ... will allow researcher and clinicians to explore and ... lives of patients , The Partners Data ... the Partners system, breaking down physical barriers for ...
(Date:11/11/2014)... Nov. 11, 2014  Forensicon, Inc., a ... pleased to announce the promotion of Yaniv Schiff ... Digital Forensics. In Schiff,s new role as Director, he ... of digital forensics examiners and provide leadership within the ... - http://photos.prnewswire.com/prnh/20141110/157719 Schiff joined ...
(Date:11/6/2014)... team of Florida State University biologists could lead to ... and survive environmental swings such as droughts or floods. ... the journal The Plant Cell , sheds light ... is organized in a cell and how plants regulate ... and others are turned off. , "If you understand ...
Breaking Biology News(10 mins):Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5Yaniv Schiff Promoted to Director of Digital Forensics at Forensicon, Inc. 2Maize analysis yields whole new world of genetic science 2
... FL, January 30, 2014 Scientists from the Florida ... awarded approximately $1.8 million from the National Cancer Institute ... signaling pathways that underlie lung cancer and to use ... Kissil, a TSRI associate professor, will be principal investigator ...
... say they have opened the window on the natural process of ... could be used to advance therapies for bone fractures and disease. ... the Feb. 13 issue of the journal Cell Reports , ... to allow adult zebra fish to perfectly replace bones lost upon ...
... in German . ... neurons in the brain. Nerve growth factors produced by the body, ... tests with GDNF have not yielded in any clear improvements. Scientists ... colleagues have now succeeded in demonstrating that GDNF and its receptor ...
Cached Biology News:Zebra fish fins help Oregon researchers gain insight into bone regeneration 2Parkinson gene: Nerve growth factor halts mitochondrial degeneration 2Parkinson gene: Nerve growth factor halts mitochondrial degeneration 3